NCT04888715View on ClinicalTrials.gov

To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

August 2, 2021

Study Completion Date

August 18, 2021

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

DWN12088

Prolyl-tRNA synthetase (PRS) inhibitor

DRUG

Pirfenidone

Pirfenidone

DRUG

Nintedanib

Nintedanib

Trial Locations (1)

13520

Cha Unitersity Bundang Medical Center, Seongnam-si

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT04888715 - To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers | Biotech Hunter | Biotech Hunter